Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Johnson & Johnson/Omrix File Evicel sBLA For General Hemostasis In Surgery

This article was originally published in The Pink Sheet Daily

Executive Summary

Anti-bleeding product’s human serum-derived Thrombin component has a September stand-alone user fee date, Omrix tells “The Pink Sheet” DAILY.

You may also be interested in...



Johnson & Johnson/Omrix’s Evicel Approved For Use In Vascular Surgery

Partners anticipate first-quarter 2008 approval of liquid fibrin sealant for general hemostasis in surgery.

Johnson & Johnson/Omrix’s Evicel Approved For Use In Vascular Surgery

Partners anticipate first-quarter 2008 approval of liquid fibrin sealant for general hemostasis in surgery.

ZymoGenetics Sees Faster Approval Of Second rhThrombin Configuration

FDA’s decision to not require Phase III study for spray version could shave 18 months off of development.

Related Content

Topics

UsernamePublicRestriction

Register

PS065860

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel